Equity cure rights explained

An equity cure is a contractual way to repair a breached financial maintenance covenant with qualifying equity proceeds, commonly funded by a sponsor. It does not rewrite operating results. Instead, the credit agreement specifies how an eligible cash contribution changes the covenant calculation after the relevant testing date.

The headline right can look broad while being operationally narrow. Its value turns on the permitted source of funds, the deadline, the recalculation method and the restrictions on repeated use. A sponsor may have enough liquidity to fund a cure and still find that the agreement does not permit the amount, timing or treatment needed to restore compliance.

The central distinction is whether cure proceeds are deemed to increase EBITDA or are applied to reduce debt. That choice changes both the immediate cash requirement and the effect of the cure on later testing periods.

What happens when a borrower exercises the cure right?

The sequence usually begins when financial statements and a compliance certificate show that the borrower failed a maintenance covenant. The relevant parent or equity investor then contributes eligible cash to the borrower or another specified loan party before the cure deadline.

The agreement may require the contribution to take the form of common equity. Some formulations also permit qualified preferred equity or deeply subordinated shareholder debt, subject to conditions. Analysts should check whether the instrument is treated as equity under the agreement, whether it carries cash-pay obligations and whether its terms could create leakage or structural claims.

Once the contribution is made, the covenant is recalculated under the cure provision. The proceeds may be:

• deemed to increase Consolidated EBITDA for the relevant fiscal quarter;
• applied, actually or notionally, to reduce funded debt;
• used in a hybrid calculation prescribed by the agreement; or
• treated differently for the covenant test and for other provisions.

A successful recalculation generally causes the borrower to be deemed compliant with the covenant as of the original test date. The related default or event of default is then treated as cured, subject to the exact drafting.

This retrospective treatment matters. The borrower did not comply when first measured; the agreement creates a contractual route to deemed compliance after the contribution.

How is an EBITDA cure calculated?

Under an EBITDA cure, the contribution is treated as if it were additional EBITDA for the relevant quarter. Suppose the maximum leverage ratio is 6.00x, covenant debt is 600 and trailing EBITDA is 95. The reported ratio is approximately 6.32x.

The minimum EBITDA cure is the amount (C) that solves:

[ \frac{600}{95 + C} \leq 6.00 ]

The required cure is 5. The calculation is driven by the gap between actual EBITDA and the EBITDA needed to support the existing debt at the permitted ratio.

This approach can be cash-efficient when the ratio is only modestly out of compliance. A dollar added to the denominator can support several dollars of debt, depending on the covenant level. That leverage effect is why lenders focus closely on over-cures and repeated cures.

An EBITDA cure can also affect later tests. If the covenant uses trailing four-quarter EBITDA, the deemed amount for the cured quarter may remain in the denominator until that quarter rolls out of the testing period. A cure made for the second quarter could therefore influence the third-quarter, fourth-quarter and following first-quarter calculations.

The drafting must be read carefully. Some agreements add the cure amount only for the breached test. Others attribute it to the relevant fiscal quarter, allowing it to remain in subsequent trailing periods. The difference can determine whether one contribution repairs a temporary miss or supports covenant compliance for the next year.

How does a debt-reduction cure change the arithmetic?

A debt-reduction cure addresses the numerator instead. Using the same example—600 of covenant debt, 95 of EBITDA and a 6.00x maximum ratio—the borrower must reduce covenant debt to 570. The required reduction is therefore 30.

[ \frac{600 - C}{95} \leq 6.00 ]

Here, (C) must be at least 30. The same initial breach requires materially more cash than the EBITDA cure example because each dollar of cure reduces debt by only one dollar.

The comparison is not always that simple. The answer depends on several defined terms:

Net leverage creates another complication. If unrestricted cash is already deducted from debt, retaining cure proceeds as cash might reduce net debt without a formal prepayment. Agreements often prevent double counting by specifying whether cash proceeds may reduce net debt, increase EBITDA or do both. Any calculation that appears unusually favourable should be tested for an express anti-duplication rule.

A debt cure can have a durable economic effect because the debt has actually been repaid. An EBITDA cure may be more efficient initially, but its benefit may end after the breached test or carry through later trailing periods until the cured quarter rolls out, depending on the drafting.

When must the contribution be made?

The cure window is normally tied to delivery of the financial statements or compliance certificate for the tested period. It may extend for a stated number of business days after the delivery deadline. The exact trigger matters when reporting is early, late or disputed.

During that window, the agreement may suspend certain lender remedies arising solely from the covenant breach. That standstill is not necessarily a blanket waiver. The borrower may be unable to borrow additional revolving loans, request letters of credit, make restricted payments or take other actions requiring no continuing default.

Key questions include:

• Does the cure period begin after actual delivery or the date delivery was required?
• Must the equity be funded before notice is given?
• Is an irrevocable cure notice required?
• Are remedies stayed automatically while the cure right remains available?
• Can representations be made as though no default exists?
• Does a separate default terminate the standstill?

These details determine whether the borrower has a usable bridge to the contribution or merely a right that exists on paper.

Why do agreements cap the number of cures?

Lenders generally accept an equity cure as protection against a temporary covenant miss, not as a permanent substitute for operating performance. Frequency limits preserve that distinction.

A typical package may regulate three dimensions:

The limits interact. A borrower could remain within the lifetime cap but be unable to cure the current quarter because it used the right too recently. Conversely, consecutive cures may be permitted while a rolling cap still prevents repeated use over a longer window.

Definitions also matter. A cure is usually counted when the right is exercised, but some drafting may count a contribution applied to more than one test differently. Analysts should not assume that one cash infusion necessarily consumes only one cure right.

These caps help distinguish volatility from sustained deterioration. If each weak quarter could be supported by deemed EBITDA, the covenant would cease to measure the operating performance lenders negotiated to monitor.

What prevents an over-cure?

An over-cure occurs when the contribution exceeds the minimum amount required for compliance and the whole of it is claimed as cure EBITDA or covenant relief. Without a restriction, excess equity could create artificial headroom in later periods.

Credit agreements address this in different ways. They may limit the deemed EBITDA increase to the amount necessary to achieve compliance. They may cap the resulting ratio at the covenant level rather than allowing additional cushion. Some permit a negotiated buffer, while others recognise the full contribution subject to an absolute ceiling.

The agreement should also be checked for a maximum cure amount linked to the EBITDA shortfall. A broadly drafted equity contribution right is not necessarily authority to add any funded amount to EBITDA.

Any excess cash may still remain in the business even if it receives no cure credit. Its treatment under cash netting, restricted payment capacity and other covenant calculations is a separate question.

Must cure proceeds be used to prepay loans?

Not necessarily. Some EBITDA cure provisions permit the cash to remain on the balance sheet for general corporate purposes. Others require all or part of the proceeds to prepay loans, often without a corresponding reduction in commitments.

A mandatory prepayment changes the economics. The equity contributor both injects cash and deleverages the borrower, even though the covenant calculation may treat the amount as additional EBITDA. Drafting should be checked for potential double counting: the borrower may be prohibited from receiving both the deemed EBITDA benefit and a debt reduction from the same proceeds for the same test.

The prepayment mechanics also affect liquidity. If revolving loans are repaid but commitments remain available, liquidity may later be redrawn, subject to draw conditions. If term loans are permanently prepaid, the capital structure changes more durably. An apparently generous cure right can therefore carry a substantial liquidity cost.

What should practitioners extract from the provision?

A useful review converts the clause into a short operating schedule:

1. Identify who may contribute and which instruments qualify.
2. Fix the contribution deadline and any notice requirements.
3. Model the minimum cure under the actual covenant definitions.
4. Determine whether the cure adjusts EBITDA, debt or both.
5. Trace the adjustment through each subsequent test period.
6. Apply rolling, consecutive-quarter and lifetime caps.
7. Test the over-cure language and anti-double-counting provisions.
8. Confirm whether proceeds trigger a prepayment and whether commitments are reduced.
9. Map the deemed cure to defaults, draw conditions and permitted actions during the cure window.

The provision should then be modelled alongside the covenant, not summarised in isolation. CreditGPT can assist with locating and comparing these mechanics across credit documents, but the decisive work is the period-by-period calculation under the executed agreement. An equity cure is worth only as much as the drafting allows when the test is actually missed.